(1-((2-phenyl-1H-imidazol-5-yl)methyl)piperidin-4-yl)(3-(trifluoromethyl)phenyl)methanone | 1463453-46-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1-((2-phenyl-1H-imidazol-5-yl)methyl)piperidin-4-yl)(3-(trifluoromethyl)phenyl)methanone
• 英文别名: (1-((2-Phenyl-1H-imidazol-5-yl)methyl)piperidin-4-yl)(3-(trifluoromethyl)phenyl)-methanone；[1-[(2-phenyl-1H-imidazol-5-yl)methyl]piperidin-4-yl]-[3-(trifluoromethyl)phenyl]methanone
• CAS: 1463453-46-4
• 化学式: C₂₃H₂₂F₃N₃O
• 分子量: 413.442
• InChiKey: JSPXSDKQCHQWDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  49
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-苯基-1H-咪唑-4-缩醛 、 piperidin-4-yl(3-(trifluoromethyl)phenyl)methanone 在 MP-BH(OAc)3 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以54%的产率得到(1-((2-phenyl-1H-imidazol-5-yl)methyl)piperidin-4-yl)(3-(trifluoromethyl)phenyl)methanone
  参考文献：
  名称：

  [EN] IMIDAZOLYL METHYL PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS
  [FR] ANTAGONISTES DES CANAUX CALCIQUES DE TYPE T IMIDAZOLYLMÉTHYLPIPÉRIDINES

  摘要：

  本发明涉及咪唑甲基哌啶化合物，其是T型钙通道的拮抗剂，用于治疗或预防与T型钙通道有关的疾病和疾病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及T型钙通道的这些疾病中使用这些化合物和组合物。

  公开号：

  WO2013148640A1

文献信息

• Imidazolyl methyl piperidine T-type calcium channel antagonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US09051299B2

  公开（公告）日：2015-06-09

  The present invention is directed to imidazolyl methyl piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.

  本发明涉及咪唑甲基哌啶类化合物，其是T型钙通道的拮抗剂，并且在涉及T型钙通道的疾病或疾病的治疗或预防中有用。本发明还涉及包含这些化合物的制药组合物，以及在涉及T型钙通道的这种疾病的预防或治疗中使用这些化合物和组合物。
• IMIDAZOLYL METHYL PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150051248A1

  公开（公告）日：2015-02-19

  The present invention is directed to imidazolyl methyl piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.

  本发明涉及咪唑甲基哌啶类化合物，其是T型钙通道拮抗剂，并且在治疗或预防与T型钙通道有关的疾病和疾病方面有用。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗与T型钙通道有关的疾病方面使用这些化合物和组合物。
• US9051299B2
  申请人：——

  公开号：US9051299B2

  公开（公告）日：2015-06-09
• [EN] IMIDAZOLYL METHYL PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS<br/>[FR] ANTAGONISTES DES CANAUX CALCIQUES DE TYPE T IMIDAZOLYLMÉTHYLPIPÉRIDINES
  申请人：MERCK SHARP & DOHME

  公开号：WO2013148640A1

  公开（公告）日：2013-10-03

  The present invention is directed to imidazolyl methyl piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.

  本发明涉及咪唑甲基哌啶化合物，其是T型钙通道的拮抗剂，用于治疗或预防与T型钙通道有关的疾病和疾病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及T型钙通道的这些疾病中使用这些化合物和组合物。